ANBT
BMRN icon

American National Bank & Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

American National Bank & Trust’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2
Closed – – 296
2016
Q4 		$0 Buy
+2
New +$172 ﹤0.01% 287

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

American National Bank & Trust's BMRN Position: Q1 2017 in Review

American National Bank & Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2017, closing a stake of 2 shares.

American National Bank & Trust first reported a position in BMRN in Q4 2016 and held it in 1 quarter. The position peaked at $0 in Q4 2016. 418 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

  • American National Bank & Trust reported no remaining BioMarin Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • American National Bank & Trust sold 2 BioMarin Pharmaceuticals shares in Q1 2017.
  • American National Bank & Trust first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • American National Bank & Trust's BioMarin Pharmaceuticals position peaked at $0 in Q4 2016.
  • 418 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on American National Bank & Trust's 13F filing for Q1 2017, filed 14 Apr 2017.